{"id":"W4391303054","doi":"10.1200/jco.2024.42.4_suppl.393","title":"Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.","year":2024,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; McMaster University; McGill University Health Centre; Health Sciences Centre; University Health Network; CancerCare Manitoba; Ottawa Hospital; Hôtel-Dieu de Québec; BC Cancer Agency; Juravinski Cancer Centre; Institute of Cancer Research; University of Manitoba; Dalhousie University; University of Alberta; Queen Elizabeth II Health Sciences Centre; Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Nivolumab; Axitinib; Medicine; Ipilimumab; Renal cell carcinoma; Pembrolizumab; Oncology; Internal medicine; Population; Metastatic melanoma; Immunotherapy; Cancer; Sunitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002378315,0.000444085,0.001050728,0.0005177667,0.0005646656,0.001006118,0.0007623865,0.0006020616,0.002802576],"category_scores_gemma":[0.004477916,0.0001731447,0.002344652,0.001416832,0.0005543351,0.0003111787,0.0003459057,0.00113676,0.0002028537],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01188831,"about_ca_system_score_gemma":0.01139806,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.5733841,"about_ca_topic_score_gemma":0.7557985,"domain_scores_codex":[0.9986632,0.0003909057,0.00007507175,0.0002018132,0.0003638291,0.0003051191],"domain_scores_gemma":[0.9981664,0.000475527,0.0005702513,0.00005211204,0.0002977644,0.0004380532],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.2652331,0.002806163,0.3090786,0.01022665,0.03787252,0.0003907171,0.0007807114,0.00381499,0.003143124,0.0012204,0.01721284,0.3482202],"study_design_scores_gemma":[0.04844224,0.02658854,0.836882,0.002586591,0.05741926,0.0004355317,0.0006667846,0.003565142,0.001152196,0.001104658,0.02099595,0.0001610861],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8713647,0.1115362,0.0003080518,0.003539735,0.0002449215,0.0004671417,0.00426139,0.00003228132,0.008245557],"genre_scores_gemma":[0.9854538,0.01143148,0.0003743456,0.0007047272,0.0001025474,0.00006489122,0.001123365,0.000007690983,0.0007370297],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4266159,"threshold_uncertainty_score":0.8582566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.102683329684702,"score_gpt":0.4055934135473228,"score_spread":0.3029100838626207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}